Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Soleus

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 28, 2023 6:15pm

79 Views

Post# 35757439

RE:Soleus

Maybe that will put the rest the conspiracy theiory that the Financing was done to keep directors ffom being booted out

scarlet1967 wrote:

BRIEF-Soleus Capital Master Fund, L.P.- Have Engaged, And Intend To Continue To Engage, In Communications With Theratechnologies Inc Board

11/28/23 - 05:57 PM ET - Reuters

Nov 28 (Reuters) - Theratechnologies Inc:

* SOLEUS CAPITAL MASTER FUND, L.P.- HAVE ENGAGED, AND INTEND TO CONTINUE TO ENGAGE, IN COMMUNICATIONS WITH THERATECHNOLOGIES INC BOARD

* SOLEUS CAPITAL MASTER FUND, L.P. REPORTS 10.5% STAKE IN THERATECHNOLOGIES INC AS OF NOV 27 , 2023 - SEC FILING

* SOLEUS CAPITAL- CONTINUE TO ENGAGE WITH THERATECHNOLOGIES’S BOARD REGARDING POTENTIAL APPOINTMENT TO BOARD, A CANDIDATE DESIGNATED BY SOLEUS CAPITAL

* SOLEUS CAPITAL-MAY ENGAGE INVESTMENT BANK TO HELP THERATECHNOLOGIES EXPLORE STRATEGIC DEAL LIKE SALE OF SOME/ALL ASSETS AND/OR CHANGE OF CONTROL Source text for Eikon: Further company coverage: